144222-22-0

Basic information

• Product Name: 1-Boc-4-(aminomethyl)piperidine
• Synonyms: 1-Boc-4-(aminomethyl)piperidine, 1-Boc-4-piperidylmethylamine;4-(aminometh;t-Butyl 4-(aminomethyl)piperidine-1-carboxylate;1-Boc-4-(aminomethyl)piperidine ,97%;4-(Aminomethyl)piperidine, N1-BOC protected 97%;1-Boc-4-aminomethylpiperi...;4-(Aminomethyl)-1-(tert-butoxycarbonyl)piperidine, tert-Butyl 4-(aminomethyl)piperidine-1-carboxylate;1,1-DiMethylethyl 4-(aMinoMethyl)-1-piperidinecarboxylate
• CAS NO: 144222-22-0
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: pharmacetical;Piperidine;Heterocyclic Compounds;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 144222-22-0.mol

Chemical Properties

• Boiling Point: 237-238 °C(lit.)
• Flash Point: >230 °F
• Appearance: Colorless to yellow/Liquid or Low Melting Solid
• Density: 1.013 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00325mmHg at 25°C
• Refractive Index: n20/D 1.473(lit.)
• Storage Temp.: Room temperature.
• Solubility: Soluble in chloroform and methanol.
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: 1-Boc-4-(aminomethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(aminomethyl)piperidine(144222-22-0)
• EPA Substance Registry System: 1-Boc-4-(aminomethyl)piperidine(144222-22-0)

Safety Data

• Hazard Codes: Xi,C,N
• Statements: 36/37/38-34-50
• Safety Statements: 26-36-45-36/37/39-24/25-23-61
• RIDADR: UN 3082 9 / PGIII
• WGK Germany: 3
• F: 10-34
• HazardClass: IRRITANT
• Hazardous Substances Data: 144222-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-boc-4-(aminomethyl)piperidine is used as a building block for the preparation of biologically active compounds and orally active platelet-activating factor antagonists. Its application is crucial in the development of drugs targeting platelet aggregation, which plays a significant role in various cardiovascular and thrombotic disorders.
Used in Enzyme Inhibition:
As an inhibitor for aspartic acid protease, 1-boc-4-(aminomethyl)piperidine is employed in the development of therapeutic agents that can modulate the activity of this class of enzymes, which are involved in various physiological processes and diseases.
Used in Cancer Research:
In the field of cancer research, 1-boc-4-(aminomethyl)piperidine is used as an inhibitor for Kinesin spindle protein, a motor protein that plays a critical role in cell division. Inhibiting this protein can lead to the development of anti-cancer drugs that target the mitotic spindle assembly checkpoint and prevent uncontrolled cell proliferation.
Used in Chemical Synthesis:
1-boc-4-(aminomethyl)piperidine is an active reactant involved in the enantioselective synthesis of N-alkyl terminal aziridines, which are important building blocks for the creation of various pharmaceuticals and agrochemicals. Its use in this process contributes to the development of chiral molecules with specific biological activities and properties.

InChI:InChI=1/C11H22N2O2/c1-10(2,3)15-9(14)13-7-5-11(4,12)6-8-13/h5-8,12H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7144-05-0 4-Aminomethylpiperidine 
• 7646-93-7 potassium hydrogensulfate 
• 452338-38-4 N-(1-tert-butoxycarbonylpiperidin-4-ylmethyl)phthalimide 
• 144222-21-9 4-({[1-Phenyl-meth-(E)-ylidene]-amino}-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 138022-91-0 tert-butyl 4-(methoxymethylene)piperidine-1-carboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 6457-49-4 4-piperidinemethanol 
• 1038352-48-5 (E)-tert-butyl 4-[(hydroxyimino)(pyridin-3-yl)methyl]-piperidine-1-carboxylate 
• 77-92-9 citric acid 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 153747-01-4 4-(phthalimidomethyl)piperidine 
• 161975-39-9 tert-butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 

Downstream Products

• 302341-64-6 tert-butoxycarbonyl-4-({[(2-aminoanilino)carbothioyl]-amino}methyl)-1-piperidine 
• 188971-17-7 4-amino-N-(1-(4-aminobutyl)piperidin-4-ylmethyl)-5-chloro-2-methoxybenzamide 
• 188971-13-3 4-amino-N-[1-(5-aminopentyl)piperidin-4-ylmethyl]-5-chloro-2-methoxybenzamide 
• 188971-75-7 4-amino-5-chloro-2-methoxy-N-((1-(6-oxo-6-phenylhexyl)piperidin-4-yl)methyl)benzamide 
• 188971-24-6 4-amino-5-chloro-2-methoxy-N-((1-(5-(thien-2-ylmethylamino)pentyl)piperidin-4-yl)methyl)benzamide 
• 616224-23-8 2-[(1-tert-butoxycarbonyl-piperidin-4-ylmethyl)-amino]-1H-benzimidazole-5-carboxylic acid ethyl ester 
• 881833-19-8 4-(N-(2-methyl-3-phenyl-2-(E)-propenyl)aminomethyl)-1-t-butoxycarbonylpiperidine 
• 494782-27-3 N-[(1R)-1-[(4-chlorophenyl)methyl]-2-(4-{2-[(methylsulfonyl)amino]phenyl}piperazinyl)-2-oxoethyl][(4-piperidylmethyl)amino]carboxamide 
• 155456-33-0 4-(Benzyloxycarbonylamino-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 389601-23-4 N-(N-tert.butoxycarbonyl-piperidin-4-yl-methyl)-3-(4'-trifluoromethylbiphenyl-2-carbonylamino)-benzoic acid amide 
• 226249-70-3 4-[{(N-(benzyloxycarbonyl)glycyl)amino}methyl]-1-(tert-butoxycarbonyl)piperidine 
• 323182-79-2 (2R)-1-{(2S,4R)-4-hydroxy-1-(3,3,3-triphenylpropanoyl)-pyrrolidin-2-yl}carbonyl-N-(4-piperidylmethyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

Efficient and scalable method for the selective alkylation and acylation of secondary amines in the presence of primary amines

Selective substitution of secondary amines in the presence of primary amines is performed by using the reaction solvent, methyl isobutylketone (MIBK), as a temporary protecting group for the primary amine. After acylation or alkylation of the secondary amine, the resulting imine intermediate is smoothly hydrolysed, leading to the free primary amine in high yield and purity. This procedure represents a cheap and scalable alternative to multistep methods requiring several protections and deprotections.

Synthetic method 1-Boc-4 - aminomethylpiperidine

The invention discloses a synthesis method of 1-Boc-4 - aminomethylpiperidine, belongs to the technical field of organic synthesis, and uses 1-Boc-4 - cyanopiperidine as a raw material, and a hydrogen-containing silicone oil is added under the catalysis of a Lewis acid to obtain 1-Boc-4 - aminomethylpiperidine. The method has the advantages of accessible raw materials, high safety coefficient and mild reaction process; meanwhile, by using the Lewis acid to lower the activation energy of reactants, the reaction activity is improved, the total yield can reach 80%, and large-scale production can be effectively realized.

Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues

Therapies addressing multiple stages of Plasmodium falciparum life cycle are highly desirable for implementing malaria elimination strategies. MMV019918 (1, 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine) was selected from the MMV Malaria Box for its dual activity against both asexual stages and gametocytes. In-depth structure-activity relationship studies and cytotoxicity evaluation led to the selection of 25 for further biological investigation. The potential transmission blocking activity of 25 versus P. falciparum was confirmed through the standard membrane-feeding assay. Both 1 and 25 significantly prolonged atrioventricular conduction time in Langendorff-isolated rat hearts, and showed inhibitory activity of Ba2+ current through Cav1.2 channels. An in silico target-fishing study suggested the enzyme phosphoethanolamine methyltransferase (PfPMT) as a potential target. However, compound activity against PfPMT did not track with the antiplasmodial activity, suggesting the latter activity relies on a different molecular target. Nevertheless, 25 showed interesting activity against PfPMT, which could be an important starting point for the identification of more potent inhibitors active against both sexual and asexual stages of the parasite.

NOVEL BENZAMIDE DERIVATIVES

The present invention provides a novel benzamide derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a 5-HT4 receptor agonist containing the same as an active ingredient. Benzamide derivatives of the present invention have a superior affinity for 5-HT4 receptors, a capability to reduce a gastric emptying time and a low toxicity, and consequently are therapeutically effective for the treatment of a variety of diseases associated with 5-HT4 receptors.

N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditio

Exploring a pocket for polycycloaliphatic groups in the CXCR3 receptor with the aid of a modular synthetic strategy

A CXCR3 pocket capable of accommodating polycycloaliphatics was explored using a modular synthetic strategy. The systematic studies reveal that the tricyclic 2-adamantane and bicyclic (iso)bornyl group are efficiently recognized by CXCR3.

PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS

Pyrrolopyrimidine derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.

HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS

Hydroxy substituted 1H-imidazo[4,5-c]pyridin-4-amines, with a hydroxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

5-HTX MODULATORS

This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT2 or 5-HT7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.

Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase

A series of conformationally restricted inhibitors of human soluble epoxide hydrolase (sEH) has been developed. Inhibition potency of the described compounds ranges from 4.2 μM to 1.1 nM against recombinant sEH. N-(1-Acetylpiperidin-4-yl)-N′-(adamant-1-yl) urea (5a) was found to be a potent inhibitor (IC50 = 7.0 nM) that was also orally bioavailable in canines.